Emergence and Magnitude of ML336 Resistance in Venezuelan Equine Encephalitis Virus Depends on the Microenvironment

Jasper Lee\textsuperscript{a}, Jyothi Parvathareddy\textsuperscript{b}, Dong Yang\textsuperscript{b}, Shruti Bansal\textsuperscript{b}, Kathryn O'Connell\textsuperscript{c}, Jennifer E. Golden\textsuperscript{d}, Colleen B. Jonsson\textsuperscript{a,b}

\textsuperscript{a}Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis, Tennessee, USA

\textsuperscript{b}Regional Biocontainment Laboratory, University of Tennessee Health Science Center, Memphis, Tennessee, USA

\textsuperscript{c}Laboratory Animal Care Unit, University of Tennessee Health Science Center, Memphis, Tennessee, USA

\textsuperscript{d}Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA

Running Head: Emergence of ML336 Resistance in VEEV

Address Correspondence to Colleen B. Jonsson, cjonsson@uthsc.edu
Venezuelan equine encephalitis virus (VEEV) is a New World Alphavirus that can cause neurological disease and death in humans and equines following transmission from infected mosquitoes. Despite the continued epidemic threat of VEEV, and its potential use as a bioterrorism agent, there are no FDA-approved antivirals or vaccines for treatment or prevention. Previously, we have reported the discovery of a small molecule, ML336, with potent antiviral activity against VEEV. To further explore the population-level resistance profiles of ML336, we developed a whole genome next-generation sequencing (NGS) approach to examine single nucleotide polymorphisms (SNPs) from virus passaged in dose escalation studies in a nonhuman primate kidney epithelial and a human astrocyte cell line, Vero 76 and SVGA, respectively. We passaged VEEV TC-83 in these two cell lines over seven concentrations of ML336, starting at 50 nM. NGS revealed several prominent mutations in the nonstructural protein (nsP) 3 and nsP4 genes that emerged consistently in these two distinct in vitro environments; notably a mutation at Q210 in nsP4. Several of these mutations were stable following passaging in the absence of ML336 in Vero 76 cells. Network analyses showed that the trajectory of resistance differed between Vero and SVGA. Moreover, the penetration of SNPs was lower in SVGA. In conclusion, we show that the microenvironment influenced the SNP profile of VEEV TC-83. Understanding the dynamics of resistance in VEEV against newly developed antiviral compounds will guide the design of optimal drug candidates and dosing regimens for minimizing the emergence of resistant viruses.
IMPORTANCE

RNA viruses, including Venezuelan equine encephalitis virus (VEEV), have high mutation rates that allow for rapid adaptation to selective pressures in their environment. Antiviral compounds exert one such pressure on virus populations during infections. Next-generation sequencing allows for examination of viruses at the population level, which enables tracking low-levels of single-nucleotide polymorphisms in the population over time. Therefore, the timing and extent of the emergence of resistance to antivirals can be tracked and assessed. We show here that in VEEV, the trajectory and penetration of antiviral resistance reflected the microenvironment in which the virus population replicates. In summary, we show the diversity of VEEV within a single population under antiviral pressure and two distinct cell types, and that population dynamics in these viruses can be examined to better understand how they evolve over time.
INTRODUCTION

Venezuelan equine encephalitis virus (VEEV) is an arbovirus belonging to the genus *Alphavirus* that causes a febrile illness in humans that may progress to life-threatening encephalitis but is often accompanied with symptoms including stupor, convulsions, and comas (1, 2). The largest and most recent major VEEV outbreak occurred in 1995 in northern Colombia and Venezuela and resulted in 85% of infected children showing neurological symptoms, as compared to 15% of infected adults. In addition, the disease had a 5% case fatality rate (1). VEEV remains infectious when aerosolized and was developed as a biological weapon by the USA and USSR during the Cold War. Despite the ratifications of the Biological Weapons Convention in 1972 that bans such activities, VEEV remains a potential biological threat with high priority (2, 3). Despite its potential threat to public health, there are currently no FDA-approved antivirals or vaccines for VEEV. Antivirals are of high importance as epidemics of VEE are unpredictable and broad-ranging vaccine programs may not be feasible in all situations (4).

In recent years, we have worked on the discovery and subsequent development of promising chemical scaffolds which have potent antiviral activity against VEEV both *in vitro* and *in vivo*. In the first studies, we reported the antiviral activity of the hit compound, CID15997213, which showed an EC$_{50}$ of 0.8 μM against the VEEV strain TC-83 (5, 6). Later, we described compounds ML336 and BDGR-4, both of which showed increased potency in inhibiting TC-83 with respective EC50 values of 32 and 47 nM (6, 7). *In vitro* studies of CID15997213 and ML336 revealed mutations in VEEV TC-83 viruses when exposed to very high concentrations of each respective compound. These mutants were plaque purified and sequenced using the Sanger method. The identification of these mutations, Y102C and D116N in nonstructural protein 2 (nsP2) and the Q210K mutation in nsP4, along with our measurements
demonstrating inhibition by ML336 in an in vitro assay using purified replication complexes, suggest the mechanism of action of these compounds interferes with the functions of those proteins in replication (8). These recent studies suggest that ML336 directly inhibit viral transcription; however, the precise mechanism is still under investigation (8). In vitro studies show that these mutations confer a 600 (Y102C) to a greater than 1600 (Q210K) fold loss in the EC50 when tested with VEEV TC-83 and ML336 (6). In recent studies, we passaged VEEV TC-83 in the presence of BDGR-4, a derivative of ML336, and used next-generation sequencing (NGS) on samples at each successive passage to follow resistance at increasing concentrations of compound (7). Interestingly, in this limited NGS study only the Q210K mutation emerged from the treatment of VEEV TC-83 with BDGR-4 in Vero 76 cells; however, a low frequency of a variety of other single nucleotide polymorphisms (SNPs) were discovered (7). Herein, we explore the emergence and magnitude of resistance-conferring mutations to ML336 in two distinct microenvironments, nonhuman primate (NHP) kidney epithelial cells which lack IFN-α (Vero 76) and a human astrocyte cell line, SVGA (9).

The trajectory and dynamics of the emergence of antiviral resistance as a function of the compound concentration are an aspect of acute viral infections that have not been explored for many RNA viruses. This is due in part to the fact that there are only a handful of effective antivirals for treatment of acute RNA virus infections such as influenza A viruses, poliovirus, and respiratory syncytial virus (10). RNA viruses whether they cause acute or persistent infections constantly generate random mutations in the genome during replication due to the high error rate of their polymerase and the lack of a proof-reading function. On average, one error is made per every 10,000 nucleotides replicated (11). This leads to the creation of viral populations that contain many related, yet individually distinct sequences within each of the virus particles.
Whether these random mutations are positively or negatively selected during an infection clearly depends on the microenvironment in which a virus establishes an infection and replicates. Potential selective pressures include the host cell type (neuronal versus epithelial cell) and immune response (and type of immune cell present) as potential drivers of the evolution of these populations and fixing of specific advantageous mutations. The resistance to antivirals is also considered an evolutionary, adaptive process (13). Of note, the maintenance of resistance mutations in the virus population is often eliminated once drug treatment stops due to the tradeoffs inherent to the cost of resistance. However this is not always the case, as observed with the seasonal H1N1 for which a positive relationship was measured for fitness and resistance of the H274Y mutation with the neuraminidase inhibitor, oseltamivir. Interestingly, serial passage of the N9 neuraminidase in a PR8 versus WSN backbone with increasing oseltamivir concentration differed in that at passage 10 (1954 µM) no mutants were observed in the N9 in the WSN backbone (14). This suggests cis-acting genetic factors may also influence the adaptive trajectory which underscores the importance of assessment of each antiviral drug against the strains circulating. Lastly, sofosbuvir, a hepatitis C virus (HCV) NS5B polymerase inhibitor, was the first antiviral that included resistance data using NGS (15, 16). Establishment of robust NGS pipelines and examination of mutational variants, low or high, will be critical to interpretation of relevance of variants over time in different cell types within an organ that may influence the metabolism and stability of the drug.

Herein, we developed and deployed an NGS pipeline for whole genome sequencing of VEEV TC-83 viral populations. In this study we used this pipeline to define viral populations from mock-treated TC-83 and ML336-treated TC-83 over several escalating concentrations or passaging after removing ML336 entirely. The objective was to provide population level
assessments of information into the dynamics of resistance of ML336 over escalating doses. In agreement with reports of others, we show that virus populations change with respect to drug concentration, which is an important consideration in the design of effective antiviral treatment protocols (17, 18). In other words, in selection of the effective dose, one must consider not only the safety and elimination of the virus, but the treatment regimen that obviates emergence of resistance. Additionally, we examined the VEEV TC-83 resistance dynamics to ML336 in two distinct biological systems: a nonhuman primate epithelial cell line (Vero 76) and a human neuronal, astrocyte cell line (SVGA). We showed that the microenvironment influenced the timing of appearance, the constellation and the penetration of SNPs associated with ML336 resistance. We also show that the nsp4 Q210 mutations are stable in the absence of compound over seven passages. As we design and test new small molecule derivatives for the alphaviruses, the pipeline developed and the results of these studies provide a framework and benchmark for selection of compounds to advance.

MATERIALS AND METHODS

Cells and Viral Culture. Vero 76 cells (ATCC CCL-131) and SVGA cells (gift from Dr. Kui Li, UTHSC) were maintained at 37°C and 5% CO₂ in complete media containing DMEM with hi-glucose and L-glutamine supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin. VEEV TC-83 (lyophilized vaccine) was obtained as a gift from Dr. Connie Schmaljohn (United States Army Medical Research Institute of Infectious Diseases, MD). Virus seed stocks were amplified in Vero 76 cells in infection media comprising of Minimum Essential Media with Earle’s salts (MEM) with 2% FBS and 1% penicillin-streptomycin. All reagents and cell culture reagents were purchased from Thermo Fisher Scientific unless specified.
Viral quantification. We used the median Tissue Culture Infectious Dose (TCID$_{50}$) to quantify virus in a 96-well plate format. Plates were seeded with Vero 76 cells overnight. Eleven 10-fold dilutions of virus samples were made, and 100 µL of each dilution was added to each well in triplicate and incubated at 37 °C, 5% CO$_2$ for 48 h. Following incubation, plates were read visually for cytopathic effect and scored. To confirm visual results, media was removed and 12 nM MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (Acros Organics) was added to each well. Plates were incubated for 4 h, after which 10% sodium dodecyl sulfate in 0.01 HCl solution was added to each well. Plates were read at an absorbance wavelength of 570 nm. Wells were scored as positive or negative and the TCID$_{50}$ was calculated based on the Reed-Muench method (19).

Plaque assays were also used to determine viral titer. Twelve-well plates were seeded with Vero 76 cells overnight. Ten series of 10-fold dilutions of virus samples were made in infection media, and 200 µL of each dilution was added to each well in duplicate and incubated at 37 °C, 5% CO$_2$ for 1 h. Following incubation, overlay media consisting of a 1:1 mix of 2% carboxymethylcellulose and 2XMEM supplemented with 5% FBS, 1% L-glutamine, 2% penicillin-streptomycin was added to each well. Plates were incubated at 37 °C, 5% CO$_2$ for 48 h. Wells were fixed with 10% formalin, stained with crystal violet, washed with Dulbecco’s phosphate buffered saline, and plaques were counted.

RT-qPCR was used to determine the amount of total viral RNA in tissue samples. cDNA of each sample was amplified using 2X SYBR Green Master Mix (Applied Biosystems) and the primers 5’-AGGAGCGCTGAACACTGATGAAGA-3’ and 5’-AGGCGAATTCATGG-AGGATGAAGAAGGG-AGGAT-3’. Reactions were run on the QuantStudio 6
(Applied Biosystems) with an initial denaturation step at 95 °C for 10 min, 40 cycles of
denaturation at 95°C for 15 sec followed by annealing/extension at 60 °C for 1 min. Viral RNA
copy number was quantified from Ct values using a standard curve generated from a linearized
plasmid standard containing a partial 250 bp sequence of the nsP2 gene.

**Assay for selection of resistant mutants.** Prior to infection, cells were seeded onto 6-well
plates and grown to 90% confluency. Cells were infected with VEEV TC-83 at an initial MOI of
1 or 0.1 as specified in text and figure legends. Resistant viruses were selected for by passaging
wild-type (WT) VEEV TC-83 in two-fold increasing concentrations of ML336, starting at 50
nM, and increasing to 100, 200, 400, 800, 1600, and lastly 3200 nM, for a total of 7 passages.
We used 250 μL of supernatant from each passage to initiate the subsequent blind passage. Four
distinct replicates were passaged in each experiment. As a control group, VEEV TC-83 was also
passed without compound in triplicate at the same time and in the same manner as the virus
was passaged with compound.

**Next-generation sequencing.** To sequence virus genomes from cell culture, 0.5 to 1 mL of
supernatant from each passage was harvested, twice-clarified by centrifugation and RNA was
isolated using Trizol LS reagent (Invitrogen). cDNA was synthesized from purified RNA using
random hexamer primers and Superscript IV. cDNA was amplified through 7 or 30 rounds of
PCR, using the Phusion High-Fidelity Kit and a set of 25 primer pairs (Table 1), using a tiling
approach that doubly covered the whole genome, making PCR fragments either 500 bp or 1 kb in
length. PCR products were purified using the Wizard SV Gel and PCR Clean-Up System
(Promega). Libraries for NGS were prepared using the Nextera XT kit (Illumina), then
sequenced on either the Illumina MiSeq or NextSeq 500. Data was analyzed using CLC Genomics Workbench v.1 (Qiagen). To process the sequencing data, reads less than 50 nucleotides in length and with a Phred score < 20 were removed. The remaining reads were mapped to the seed stock consensus sequence, and variants were identified either with a minimum frequency above 1% in all reads at positions with a minimum coverage of 400, or, if the quality and quantity of reads were sufficient, with a minimum frequency above 0.5% in all reads at positions with minimum coverage of 1000 (20, 21).

In Vivo Assessment of VEEV TC83 in the presence and absence of ML336 by NGS. All mouse studies were reviewed by and approved by the UTHSC IACUC in Animal Care and Use Protocol Number 17.057. Five to six-week-old, female, C3H/HeN mice were obtained from Charles River Laboratories and randomly assigned into one of three treatment groups: Group 1 – uninfected control with vehicle; Group 2 – TC-83 and vehicle only; Group 3 – TC-83 and ML336 at dosing concentration of 24 mg/kg/day. Mice were dosed via intraperitoneal (IP) injection twice per day with vehicle (25% polyethylene glycol 400, 10% Kolliphor® RH40, 65% water) or with vehicle containing 12 mg/kg ML336, starting 2 h before infection for eight days. Mice were infected intranasally (IN) with VEEV TC-83 diluted to a concentration of $1 \times 10^7$ pfu/30 µL, 15 µL per naris in PBS. PBS was used in place of virus for the vehicle-only control group. Mice were weighed daily and checked twice daily for mortality and morbidity, and subgroups of the VEEV TC-83 infected mice (four mice in each subgroup) were humanely sacrificed on Day 4, 7, or 14 post infection (dpi), or when they either reached > 30% weight loss of the starting body weight, or close to 30% and a clinical score of 0.8 on a euthanasia score sheet approved by the IACUC. Following euthanasia, the whole brain, including the olfactory
bulbs, was removed from each mouse. One half of the brain was homogenized in 1 ml of DPBS using the Omni Bead Mill. We added an equal volume of TRIzol reagent (Invitrogen) to extract total RNA from brain tissue. Because brain tissue has a high lipid content, the RNA from TRIzol was further purified. 2.5uL of the total RNA, equivalent to 5 mg of homogenized brain originally extracted in TRIzol Reagent, was purified with the MagMAX mirVana using the KingFisher Flex (Thermo Scientific). RNA concentration was measured by the Qubit Fluorometer 4 (Invitrogen) using the Qubit RNA HS assay kit (Invitrogen) and stored at -20°C for RT-qPCR to be carried out the following day. Approximately 20 μg of total RNA was obtained from 5 mg of tissue. RT-qPCR was conducted to quantitate viral RNA in mouse brain specimens. 400 ng RNA per sample was taken for assessment using the Superscript III Platinum One step qRT-PCR kit (Invitrogen) using a Taqman probe (5’-6-FAM-ACGCGCTAGGGCTCACAGGCGAG-[TAMRA]-3’ (Applied Biosystems), and primers to the VEEV TC83 nsp2 gene (forward, 5’-AGGAGCGCTGAACACTGATGAAGA-3’, reverse, 5’-AGGGAATTCATGGAAGGGAGGAT-3’). The RT-qPCR was analyzed on a Quantstudio 6 Flex system for 40 cycles. Viral copy number in the brain samples was calculated using a standard curve made from 10-fold dilutions of VEEV TC83 RNA from the master seed stock. For NGS, the cDNA, PCR amplification, and NGS were performed as described above. In brief, mouse brains were normalized as ½ brain per ml of DPBS. We measure the Ct values from the brain for the cDNA amplification step. We also normalized the amplicons by our pooling strategy to obtain even coverage. Lastly, we normalized each sample to the same concentration of amplicon prior to library production.

**Network Analysis.** The whole genome consensus sequences from each sample were obtained using CLC Genomics Workbench v.12 (Qiagen). Sequences were aligned using MUSCLE and
mapped by the program PopArt v. 1.7, utilizing a Minimum Spanning Tree to plot each sequence.

Data availability. All the NGS data from the studies herein is publicly available at the BioProject accession number PRJNA655204.

RESULTS

Development of a whole genome next-generation sequencing approach to assess single nucleotide variation in VEEV TC-83. In order to accurately identify single nucleotide polymorphisms in VEEV TC-83, we needed a method to generate enough sequences to provide sufficient coverage and depth across the entire genome to detect low-frequency variants. To achieve this goal, we developed a tiling method for whole genome amplification in which we designed primers to create amplicons of approximately 1000 or 500 base pairs long while ensuring the entire VEEV TC-83 genome was covered twice (Figure 1A). In total, 25 primer pairs were identified as providing an efficient, and a similar level of amplicon product, using RNA isolated from our seed stock of WT VEEV TC-83 (Table 1). To ensure the correct sequences were amplified, amplicons were purified by agarose gel electrophoresis and Sanger sequencing. This also provided a reference for the VEEV TC-83 genome based on Sanger. Primer sequences were optimized over time to produce equivalent amounts of product from the PCR reaction. Initially, all amplicons were evaluated separately to ensure evenness in coverage. Secondly, we evaluated various approaches to pooling amplicons for sequencing. The optimal pooling noted from assessment of NGS data, was one in which we sorted each primer pair into five different groups for PCR amplification (Figure 1A). We pooled the PCR products from those groups together before purifying, preparing libraries and NGS.
We performed NGS on the pooled products to assess the coverage and depth of sequencing data we could obtain. We examined the data on low frequency variants at a confidence level of 99.999%, according to standards outlined by Ladner et al. (20, 21). In the alignment step, we used a full genome sequence published on GenBank of VEEV TC-83 (Accession: L01443.1 GI: 323714) to provide an initial reference (22). Thereafter, we used our consensus sequence as the reference. As shown in Table 2, there were two differences between the GenBank reference sequence and the consensus sequence of our seed stock virus. We noted nucleotide changes of T7208C and C11386T. These mutations are located in the nsP4 gene and the 3’ untranslated region of the genome, respectively, and as such neither causes an amino acid change. The mapped reads showed 100% coverage throughout the entire genome (Figure 1B). In addition, more than 1000X depth of coverage was obtained except at the very end of the 3’ untranslated region, surpassing the benchmarks necessary for confidence in identification of variants. In summary, the tiling method was sufficient in providing us the amount of sequencing reads necessary to detect and call variants.

Emergence and magnitude of VEEV TC-83 resistance to ML336 at increasing concentrations. To determine how VEEV TC-83 evolves and adapts to ML336 at different concentrations, we infected VEEV TC-83 at a MOI =1.0 in Vero 76 cells a 6-well plate in which each well has 600,000 cells (Figure 1C). This provided a sufficient population size to determine if any mutants were preexisting in the mock-treated and for sampling the standing genetic variation/sequence space of the seed stock (approximately 10^9/ml). VEEV-TC83 grows rapidly to very high titers, and hence at this MOI, we were sampling approximately 0.6% of the available seed stock virions. All virus was removed following infection with by washing with
DPBS after which fresh media or media with compound was added. We started the first passage at 50 nM, a concentration slightly above the EC_{50} (30 nM), and increased the concentration of ML336 two-fold at each passage, namely 100, 200, 400, 800, 1600, and 3200 nM concentrations (6). The experiment included four biological replicates (R1-R4). As a control, VEEV TC-83 was passaged in the absence of ML336 in each experiment in an identical manner as the virus with compound. RNA was isolated from twice-clarified supernatant at each passage and sequenced each sample as described in the Materials and Methods. We also assessed the amount of virus after each the passages, R1 and R2 (Figure 2).

Each replicate at each concentration was evaluated for SNPs (Figure 3, Table 3). We only considered SNPs that reached a percentage of over 10% of the population, as those that emerged between 1-10% were usually not stable and did not penetrate over time. Replicate 1 (R1) produced the highest number of SNPs, with 12 in total. In R2, four SNPs became dominant in the population by the third passage. Replicates R3 and R4 only saw two major SNPs. The identity of the SNPs detected were distinct; however, R1, R2, and R4 all showed a Q210R mutation in nsP4. R1 and R2 shared an E97Q SNP in nsP2 and Y87F SNP in nsP4, as well as a synonymous mutation at position A461 in nsP3. R1 was the only replicate where a significant percentage of SNPs in structural genes emerged, all within in the E1 gene and all synonymous mutations. A second nsP4 Q210 mutation, with an amino acid change into histidine, was observed in R1 at a lower frequency than Q210R. The emergence of E118V and G786G in nsP2, and A201V and H414Y in nsP4 were also unique to R1. A nucleotide change at R305 in nsP4 was found in R2 only. The I268I mutation only appeared in R3, while the only nsP1 mutation, R220C, was found in nsP4. No SNPs above our variant calling cutoff were detected in virus-only controls where TC-83 was passaged without the presence of ML336 (data not shown).
In R1, R2, and R4, SNPs appeared at a concentration of 100 nM or 200 nM of ML336 and increased rapidly up to 400 nM, after which the magnitude of SNP penetration appeared to plateau, especially if the percentage of the SNP in the population reached over 90%. However, in R1, a few SNPs, including H414Y (nsP4) and S275S (E1), appeared at 100 nM and then immediately disappeared from the population in subsequent passages. The E97Q mutation in R1 and R2 showed two distinct trajectories, where it would either disappear and reappear or slowly increment in the population. Both SNPs that reached consensus in R3 appeared at significantly high percentages at 100 nM. Lastly, both major SNPs found in nsP4 exhibited trajectories where both SNPs increased in percentage at a much slower rate, with the Q210R mutation only peaking at 3200 nM (Table 3). In summary, these results show that TC-83 evolved resistance to ML336 through a variety of paths but converged in a resistance solution at the Q210 amino acid position.

**Mutant populations stayed consistent when passaging in the absence of ML336.** To determine whether the mutations generated in the previous experiment were stable, each replicate was passaged an additional seven times in Vero 76 cells without the presence of ML336. The starting virus sample used was from the 3200 nM supernatant from each replicate in the previous experiment (referred to as VEEV TC-83/3200) which was inoculated at a MOI of 1. At each passage, virus supernatant was collected and sequenced in the same manner as before. As shown in Figure 4 and Table 4, the major mutations in each population remained similar through each passage, although there were two interesting cases. Firstly, the nsP2 E97Q mutation in R2 disappeared from the population after one passage and did not reappear. Secondly, the R220C amino acid change in nsP1 in R4 fluctuated in percentage through the seven passages, but we observed that all the percentages were higher than when the virus was passaged in the
presence of ML336. In conclusion, these combinations of mutations were stable and did not cause a loss in fitness to the viral population in the absence of ML336, since they were maintained well through repeated passages.

**Passaging TC-83 through increasing concentrations of ML336 in the SVGA cell line.** The Vero 76 cell line is deficient in type-I IFN production, thus creating a cellular environment that allows viruses to easily proliferate (9). In order to test the emergence of resistance to ML336 in an environment that more closely resembles that of a natural infection and creates a higher barrier to replication, we selected the SVGA cell line as our model. The SVGA cell line is derived from human astrocyte cells, and VEEV has been shown to replicate in astroglia in the central nervous system (23, 24). To show SVGA was a viable model for VEEV TC-83 infection, we performed a time course infection of SVGA cells. TC-83 reached a titer of over $1 \times 10^9$ TCID<sub>50</sub>/ml by 24 h, which is in line with titers from infection of Vero 76 cells (data not shown). Thus, we showed that TC-83 was able to productively infect the cell line.

With this result, we passaged and sequenced TC-83 in SVGA in the same manner as with Vero 76, using the same ML336 concentrations as before. To serve as a control, we passaged the virus without the addition of ML336. We sequenced all four replicates at each concentration (**Figure 5A**, **Table 5**) and three replicates of virus without ML336 (**Figure 5B, Table 5**). In all four replicates passaged with ML336, the Q210H mutation arose to become the most dominant mutation, again appearing within 100-200 nM of ML336. In addition, the Q210R mutation also appeared in all replicates at a similar timing, though in each replicate it followed a trajectory where it was less prominent than the Q210H mutation. Interestingly, in R1, we discovered a second nucleotide mutation in the Q210H mutation in which cytosine instead of the usual thymine arose at nucleotide position 6332, and the cytosine mutant became more dominant than...
the thymine as ML336 concentration increased in subsequent passages. The trajectories of each replicate compared to each other were slightly more uniform, as the A461 synonymous mutation in nsP3 and the Y87F and R305 mutations in nsP4 appeared in all replicates, starting at 100 nM. The A425V mutation in nsP4 was shared between R1 and R4, the E213D mutation in nsP4 was shared between R1 and R2, and the E118V mutation was shared between all replicates except R2. SNPs unique to each replicate mostly occurred in nsP2, where the P644S (R1), D116N (R2), and E87A (R4) mutations appeared. R2 also contained a D253D mutation in nsP1, and mutations in E1 appeared in R1.

Lastly, in the virus-only controls, the only SNPs that emerged were located in genes coding for structural proteins (Figure 5B, Table 5). Notably, the E3K mutation in the E2 gene was found in both R1 and virus control 3 (VC3), while the P78S mutation was found in both VC2 and VC3. A unique Y107Y mutation also emerged in VC1. Taken together, these results show that the mutation trajectory of TC-83 when subjected to ML336 diverges in SVGA cells compared to Vero 76 cells.

NGS of VEEV TC-83 in brains from a lethal mouse model treated with ML336 did not detect resistance variants.

Next, we aimed to examine the potential of ML336 resistance in vivo, using the mouse strain C3H/HeN, in which TC-83 can cause a lethal infection at $1 \times 10^7$ pfu (7, 25). Previously, we have reported that IP administration of ML336 at 25 mg/kg/day, twice per day (BID), gave complete prophylactic protection (n=8) when challenged with VEEV TC83 (25). Based on these data, we selected timepoints at days 4, 7, 8 and 14 to examine brains for the presence of viral RNA by MiSeq NGS using the aforementioned approached developed for our in vitro studies.
Groups of C3H/HeN mice were infected with 1x10⁷ pfu TC-83 and treated with either 24 mg/kg/day ML336 or vehicle, starting 2 h before infection for eight days. Mice were monitored for survival and weight change (Fig. 6A, 6B). As shown previously, treatment of mice with ML336 at 24 mg/kg/day over 8 days provided protection (n=7/8) through day 14 with only a single mouse succumbing to disease on 8 dpi (Fig. 6A) (6, 25). In the group with VEEV TC83, a sharp decline in body weights was observed beginning 5 dpi, whereas the ML336 treated mice continued to have similar level of weight gain as the noninfected mice (Fig. B). Brains from sacrificed mice on 4, 7, 8 or 14 dpi were homogenized, and RNA was extracted and processed for quantification through RT-qPCR to confirm the amount of virus present before NGS (Fig. 6C). SNPs detected in the brains of TC-83 infected mice at percentages above 10% are shown in Table 6. The ML336-treated mouse brains did not result in a sufficient number of sequencing reads that allowed for analysis and featured uneven depth of coverage; however, we were able to pull SNPs from the 6K portion of the genome for one sample where SNPs were observed above 10% penetration. None of the SNPs found in this experiment had been previously found to confer resistance to ML336.

Network Analysis of TC-83 in Different Microenvironments Reveals Different Trajectories of Resistance to ML336

After determining the major SNPs that emerged in the previous in vitro and in vivo experiments, we aimed to analyze these data using network analysis. Consensus sequences for the full length genome for each of the samples from each of the experiments described above, along with the original reference sequence (Accession #L01443.1) and sequences from the seed stocks used for passaging, were aligned with the MUSCLE algorithm and plotted using PopArt v.1.7, which
allowed us to visualize sequence differences (26). We used a minimum spanning tree to plot the sequences, which are shown in Figure 7. The resulting graph shows that TC-83 lineages diverged based on the host (Vero 76, SVGA or mouse brain) from which they were isolated. We observed no overlap in trajectory between virus sequences from Vero 76-derived and SVGA-derived samples. In addition, samples in which TC-83 was passaged through SVGA or used to infect C3H/HeN mice, but without addition of ML336, were included, and these samples also resulted in distinct network branches. The network analysis shows the random and ML336-influenced genetic diversity of the VEEV TC-83 virus population in each environment. Of note, the SNPs detected from the wild-type virus diverged from the original consensus in one SVGA-passaged virus and in TC-83 isolated from mouse brains.

**DISCUSSION**

In this study, we examined the dynamics of the evolution of resistance to ML336 in VEEV strain TC-83 in three distinct environments. Our experiments were designed to address how different environments for the virus would affect these trajectories. Our network analysis shows that the microenvironment does indeed have an impact on the evolution of drug resistance. We observed similarities between the ML336 resistance-conferring SNPs that emerged in each tested microenvironment and in the timing of emergence; however, the extent of virus genomes containing these SNPs as well as the timing varied between these groups. Moreover, the sites of random SNPs were distinct for each population. As far as we are aware, using network analysis to compare and map the trajectory of viral drug resistance from whole genome sequencing has not been previously reported.
In previous studies, three mutations that conferred resistance to ML336 were discovered, namely the Y102C and D116N mutations in the nsP2 gene, and the Q210K mutation in the nsP4 gene, with the Q210K mutation causing the strongest loss of potency \(^{(5, 6)}\). Because of those prior results, we had expected to find these mutations emerging in the TC-83 population when challenged with ML336 in Vero 76 cells. Notably, while the Q210K mutation was detected in R3, distinct mutations at that amino acid position were found in the other replicates, namely Q210R and Q210H. In R1, multiple Q210 mutations appeared simultaneously. The changes at Q210 to basic amino acids suggests that the mutation from glutamine to a positively charged amino acid, whether it is lysine, histidine, or arginine, is particularly important in conferring resistance to ML336. The previously discovered Y102C and D116N nsP2 mutations were not found at any passage in any sample when passaging through Vero 76 cells, but when passaging through SVGA cells, the D116N mutation did appear for four passages in one replicate, starting at 100 nM, before disappearing from the population entirely. Interestingly, a mutation at E118V, also in nsP2, appeared in both experiments and followed a similar trajectory of peaking at 100 nM and eventually disappearing. The relative lack of prominent nsP2 SNPs past the first two passages may suggest that D116N and E118V are transitionary mutations that confer resistance but come with a higher fitness cost than the mutations at Q210 in nsP4.

When comparing the SNPs found between the Vero 76 and SVGA passaging experiments, we found that there was not a large difference in terms of the SNPs that arose to significant percentages, as mutations at A461 in nsP3, and Y87, Q210, and R305 appeared frequently throughout all samples, and few new SNPs in the non-structural genes were found in the SVGA-passaged viruses. However, SNPs from SVGA-passaged TC-83 emerged more slowly than from Vero-passaged TC-83; with the exception of Q210, most SNPs took three or four
passages to reach a consensus in Vero 76 cells, while in SVGA, very few SNPs were able to reach a consensus, even Y87F and R305R. This result suggests that SVGA may provide a modest cellular immune response challenge to TC-83, but it is possible that in both systems the virus overwhelms the cells once the SNPs conferring ML336 resistance emerge and are selected. Remarkably, most of these mutations were not lost in the absence of ML336, which suggests that the fitness cost is not very high, at least for the Q210 mutations where they stayed near-consensus level regardless of the identity of the other SNPs present. It was difficult to assess the SNPs in C3H/HeN mouse brains due to the low depth of coverage, particularly in genes where SNPs known to confer resistance to ML336 are found. However, the variety of SNPs that were detected between individual untreated mice underscores the genetic diversity of each viral population that is generated during infections. In addition, there was little to no overlap between SNPs found *in vitro* and *in vivo*, again highlighting the differences in microenvironments.

For most of the passaging experiments, we did not confirm whether each major mutation occurred on the same individual viral genomes. However, for each replicate of the Vero 76-ML336 passaging experiment (**Fig. 3**), we isolated RNA from the final passage, converted it to cDNA, then ran a PCR using primers that covered the portion of the genome containing all of the major nsP3 and nsP4 mutations, ligated the products into a plasmid system, and ran plasmids through Sanger sequencing. For the most part, each individual sequence contained all of the SNPs that were located in the particular replicate tested (data not shown). This result seems to suggest that, while Q210 mutations may be necessary for resistance to ML336, other SNPs such as Y87F are often found together on the same viral genomes and may play a role in sustaining viral fitness. Further experiments such as using mutagenesis to create mutant TC-83 clones...
containing these SNPs or sequencing samples using Oxford Nanopore MinION sequencer would
better determine the relationships between each individual SNP.

The passaging and sequencing methods used in this study are the same as those
mentioned in our study on BDGR-4, where Vero 76 cells were used as the passaging medium. In
that study, several major SNPs in nsP3 (A461A) and nsP4 (Y87F, Q210K/R/H, E213D, R305R)
emerged in those VEEV populations (7). It is not surprising that similar SNPs emerged in this
study, as BDGR-4 is a derivative of ML336 within the same amidine structural class. The results
reflect that structurally similar compounds elicit similar adaptations in the VEEV genome,
although SNPs conferring resistance emerged more slowly to BDGR-4 than they did for ML336.

In addition, the data presented here aligns with data in our previous studies that suggests that
ML336 and its analogs directly target the polymerase, and disrupts interactions between nsP4
and nsP2 that, in turn, inhibits the synthesis of the positive and negative strands and the
subgenomic RNA (5-8). However, it is still unclear what exact effect these mutations have on
nsP4, as they all fall under a region where there is no known activity or function throughout all
alphaviruses (27).

Since the disclosure of ML336 and BDGR-4, we have continued to work on the
development of new compounds. Lead candidates will be assessed for resistance in the same
manner. Testing the trajectory of resistance in more complex systems, such as in primary
neuronal cells, combination therapy, and multiple-cell systems resembling the central nervous
system and blood-brain barrier, or in more mouse models, will allow us to examine the effects of
more complex environments on antiviral resistance in VEEV in more detail.

ACKNOWLEDGEMENTS
This work was supported by NIH grant 5R01AI118814 to CBJ, JEG, and Donghoon Chung (University of Louisville). We thank Mariah Taylor and Evan Williams for their comments in review of this manuscript. We thank Mariah Taylor for her experimental support in RNA isolation.
1. Rivas FD, L A; Cardenas, V M; Daza, E; Bruzon, L; Alcala, A; De la Hoz, O; Caceres, F M; Aristizabal, G; Martinez, J W; Revelo, D; De la Hoz, F; Boshell, J; Camacho, T; Calderon, L; Olano, V A; Villarreal, L I; Roselli, D; Alvarez, G; Ludwig, G; Tsai, T. 1995. Epidemic Venezuelan Equine Encephalitis in La Guajira, Colombia, 1995. J Infect Dis 1997:828-832.

2. Zacks MA, Paessler S. 2010. Encephalitic alphaviruses. Vet Microbiol 140:281-286.

3. Paessler S, Weaver SC. 2009. Vaccines for Venezuelan equine encephalitis. Vaccine 27 Suppl 4:D80-85.

4. Aguilar PV, Estrada-Franco JG, Navarro-Lopez R, Ferro C, Haddow AD, Weaver SC. 2011. Endemic Venezuelan equine encephalitis in the Americas: hidden under the dengue umbrella. Future Virology 6:721-740.

5. Chung DH, Jonsson CB, Tower NA, Chu YK, Sahin E, Golden JE, Noah JW, Schroeder CE, Sotsky JB, Sosa MI, Cramer DE, McKellip SN, Rasmussen L, White EL, Schmaljohn CS, Julander JG, Smith JM, Filone CM, Connor JH, Sakurai Y, Davey RA. 2014. Discovery of a novel compound with anti-venezuelan equine encephalitis virus activity that targets the nonstructural protein 2. PLoS Pathog 10:e1004213.

6. Schroeder CE, Yao T, Sotsky J, Smith RA, Roy S, Chu YK, Guo H, Tower NA, Noah JW, McKellip S, Sosa M, Rasmussen L, Smith LH, White EL, Aube J, Jonsson CB, Chung D, Golden JE. 2014. Development of (E)-2-((1,4-dimethylpiperazin-2-ylidene)amino)-5-nitro-N-phenylbenzamide, ML336: Novel 2-amidinophenylbenzamides as potent inhibitors of venezuelan equine encephalitis virus. J Med Chem 57:8608-8621.

7. Jonsson CB, Cao X, Lee J, Gabbard JD, Chu YK, Fitzpatrick EA, Julander J, Chung DH, Stabenow J, Golden JE. 2019. Efficacy of a ML336 derivative against Venezuelan and eastern equine encephalitis viruses. Antiviral Res 167:25-34.

8. Skidmore AM, Adcock RS, Jonsson CB, Golden JE, Chung DH. 2019. Benzamidine ML336 inhibits plus and minus strand RNA synthesis of Venezuelan equine encephalitis virus without affecting host RNA production. Antiviral Res 174:104674.

9. Emeny JMM, Michael J. 1979. Regulation of the Interferon System: Evidence that Vero Cells have a Genetic Defect in Interferon Production. J Gen Virol 43:247-252.

10. De Clercq E, Li G. 2016. Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev 29:695-747.

11. Drake JWH, John J. 1999. Mutation rates among RNA viruses. PNAS 96:4.

12. Lauring AS, Andino R. 2010. Quasispecies theory and the behavior of RNA viruses. PLoS Pathog 6:e1001005.

13. Irwin KK, Renzette N, Kowalik TF, Jensen JD. 2016. Antiviral drug resistance as an adaptive process. Virus Evol 2:vew014.

14. Farrukee R, Butler J, Reading PC, Hurt AC. 2019. Characterization of substitutions in the neuraminidase of A(H7N9) influenza viruses selected following serial passage in the presence of different neuraminidase inhibitors. Antiviral Res 168:68-75.

15. Donaldson EF, Harrington PR, O’Rear JJ, Naeger LK. 2015. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology 61:56-65.
16. Xu S, Doehle B, Rajyaguru S, Han B, Barauskas O, Feng J, Perry J, Dvory-Sobol H, Svarovskaia ES, Miller MD, Mo H. 2017. In vitro selection of resistance to sofosbuvir in HCV replicons of genotype-1 to -6. Antivir Ther 22:587-597.

17. Renzette N, Caffrey DR, Zeldovich KB, Liu P, Gallagher GR, Aiello D, Porter AJ, Kurt-Jones EA, Bolon DN, Poh YP, Jensen JD, Schiffer CA, Kowalik TF, Finberg RW, Wang JP. 2014. Evolution of the influenza A virus genome during development of oseltamivir resistance in vitro. J Virol 88:272-281.

18. Foll M, Poh YP, Renzette N, Ferrer-Admetlla A, Bank C, Shim H, Malaspinas AS, Ewing G, Liu P, Wegmann D, Caffrey DR, Zeldovich KB, Bolon DN, Wang JP, Kowalik TF, Schiffer CA, Finberg RW, Jensen JD. 2014. Influenza virus drug resistance: a time-sampled population genetics perspective. PLoS Genet 10:e1004185.

19. Reed LJM, H. 1938. A Simple Method of Estimating Fifty Per Cent Endpoints. Am J Hyg 27:493–497.

20. Wang C, Mitsuya Y, Gharizadeh B, Ronaghi M, Shafer RW. 2007. Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res 17:1195-1201.

21. Ladner JT, Beitzel B, Chain PS, Davenport MG, Donaldson EF, Frieman M, Kugelman JR, Kuhn JH, O’Rear J, Sabeti PC, Wentworth DE, Wiley MR, Yu GY, Threat Characterization C, Sozhamannan S, Bradburne C, Palacios G. 2014. Standards for sequencing viral genomes in the era of high-throughput sequencing. MBio 5:e01360-01314.

22. Kinney RM, Johnson BJ, Welch JB, Tsuchiya KR, Trent DW. 1989. The full-length nucleotide sequences of the virulent Trinidad donkey strain of Venezuelan equine encephalitis virus and its attenuated vaccine derivative, strain TC-83. Virology 170:19-30.

23. Jackson ACR, John P. 1997. Apoptotic cell death is an important cause of neuronal injury in experimental Venezuelan equine encephalitis virus infection of mice. Acta Neuropathol 93:349–353.

24. Schoneboom BAC, Kristen M.K.; Marty, Aileen M.; Grieder, Franziska B. 2000. Inflammation is a component of neurodegeneration in response to Venezuelan equine encephalitis virus infection in mice. J Neuroimmunol 109:132–146.

25. Julander JG, Skirpstunas R, Siddharthan V, Shafer K, Hoopes JD, Smee DF, Morrey JD. 2008. C3H/HeN mouse model for the evaluation of antiviral agents for the treatment of Venezuelan equine encephalitis virus infection. Antiviral research 78:230-241.

26. Leigh JW, Bryant D, Nakagawa S. 2015. popart: full-feature software for haplotype network construction. Methods in Ecology and Evolution 6:1110-1116.

27. Rubach JK, Wasik BR, Rupp JC, Kuhn RJ, Hardy RW, Smith JL. 2009. Characterization of purified Sindbis virus nsP4 RNA-dependent RNA polymerase activity in vitro. Virology 384:201-208.
Figure Legends

Figure 1. Methods for amplifying viral genomes for sequencing and detecting small nucleotide variations, and for passaging TC-83 through increasing concentrations of ML336. (A) Schematic for the tiling PCR method. Each colored bar represents an amplicon generated by a singular primer pair and is placed relative to the portion of the VEEV TC-83 genome it covers. Primer pairs of the same color were pooled together during PCR setup. Pools were combined prior to DNA purification. (B) Sample coverage graphs from applying the tiling method and deep sequencing the resulting amplicons. WT VEEV TC-83 was used to produce these graphs, using a total of 622,583 mapped reads. The top graph shows the depth and coverage throughout the genome, while the bottom graph shows coverage using a cutoff of 1000 depth. (C) Schematic for the passaging of VEEV TC-83 in the presence of 2-fold increasing concentrations of ML336. The starting concentration was 50 nM. Vero 76 cells were grown for two days in a six well plate and infected at the start of the experiment with 1 MOI. For each experiment, replicates are marked as R1, R2, R3 and R4.

Figure 2. TCID50 data for R1 and R2 from passaging VEEV TC-83 in Vero 76 cells through increasing concentrations of ML336. For the biological replicates R1 and R2 (Figure 2), we measured the titer of the virus after each passage at the time the supernatant was collected (48 hpi) and clarified. All supernatant was stored at -80°C until virus titers were assessed using the TCID50 assay, which is reported in this figure as TCID50/ml.
Figure 3. Four biological replicates of VEEV TC-83 passaged in Vero 76 cells over escalating doses of ML336 reveal four distinct paths to a common solution of resistance. Each well with approximately 600,000 cells was infected with an initial MOI of 1, washed to remove any unbound virus, and then passaged in the presence of 50, 100, 200, 400, 800, 1600 or 3200 nM concentrations. The first five passages (50, 100, 200, 400, 800) of each replicate, R1, R2, R3, and R4, are plotted. Each SNP that was found in at least 10% of all reads in at least one passage were defined and graphed for each passage/ML336 concentration. Each unique SNP is represented by an individual color.

Figure 4. Most SNPs show stability over seven passages in the absence of ML336. Supernatant from VEEV TC-83/3200 were used to infect a six well plate seeded with Vero 76 cells for 1 h at an initial MOI of 1. After 1 h, media was removed and replaced with fresh complete MEM. Supernatant from each passage was collected at 24 h and subjected to NGS as described in the Materials and Methods. 250 μL of supernatant was used to infect new cells (Passage 2). Passages were repeated 5 additional times. The y-axis shows the percentage of SNPs relative to the WT population.

Figure 5. Passaging TC-83 in SVGA cells through increasing concentrations of ML336 showed that ML336 exerted a stronger environmental pressure. Each well was infected with an initial MOI of 0.1. All mutations appearing in at least 10% of all sequence reads found in at least one passage were included, plotting their percentage in the population over each ML336 concentration. (A) The first five passages of each experimental replicate were plotted. A
distinction has been made between the two Q210H mutations to show that the A to T mutation is more common. (B) Graphs of three virus-only controls, showing all passages. All mutations occurred in genes coding for envelope proteins.

**Fig. 6. Timepoints chosen for NGS In vivo efficacy of ML336 tested in C3H/HeN mice**

**Challenged with VEEV TC-83.** Mice were IN infected with TC-83, and treated with either ML336 (IP; 24mg/kg/day) or vehicle for 8 days starting from 0 dpi. Survival (A) and weight change (B) were monitored over 14 days. The survival rates were compared between the ML336-treated and placebo-treated groups using Log-rank (Mantel-Cox) test. (C) RT-qPCR data for each individual mouse. *** represents P< 0.001. Days marked with red triangles were time points when mouse brains were collected for RNA extraction.

**Figure 7. Whole genome consensus sequence network shows that VEEV TC-83 evolves resistance through different trajectories in distinct microenvironments.** Consensus sequences were obtained from NGS sequencing data analysis, then aligned using MUSCLE and plotted based on sequence differences. Samples were grouped and labeled based on virus source. Each tick represents the number of nucleotide differences between sequences. Reference used was taken from GenBank (Accession #L10443.1). Samples in the Seedstock, SVGA-VC, and C3H/HeN groups were not treated with ML336. *In vitro* samples are named by cell type, compound or control, and ML336 concentration or passage number. *Samples include: All seed stocks, C3H/HeN day 8, ML336 R1 50-100, ML336 R2 50, ML336 R3 50, ML336 R4 50-800, SVGA R1 50-200, SVGA R2 50-200, SVGA R3 50-100, SVGA R4 50-100, SVGA VC1 P1-7, SVGA VC2 P1-5, SVGA VC3 1-7.
Table 1. Primer pairs used to amplify the full genome of VEEV TC-83.

| Primer Set Number | Direction | Sequence                          |
|-------------------|-----------|-----------------------------------|
| 1                 | F         | ATAGGCGGCGCATGAG                   |
|                   | R         | CCCTTCGTAGCGACACG                  |
| 2                 | F         | ATAGGCGGCGCATGAG                   |
|                   | R         | GCACAAAGAATCCCTCGC                |
| 3                 | F         | CAAGTGGCTGGTTTACCAGG              |
|                   | R         | GGTAATGAGAGGTGACGGC               |
| 4                 | F         | TATGGGAAGCCCTCACG                 |
|                   | R         | TACCTGGTTAGAAGCTCACG              |
| 5                 | F         | CAGGAAATGTTAGAAGGAC              |
|                   | R         | GAGCGCTCTGAGAGTACC                |
| 6                 | F         | CCACCATGCTGTACAGG                |
|                   | R         | TTATCCATGGTGCTGCC                 |
| 7                 | F         | GCTTTGTGTTTGCATG                 |
|                   | R         | CATAATTGCACAGTGTACC              |
| 8                 | F         | GTGGAACATAGCAGG                  |
|                   | R         | AAATTCCTCGTTCTTCAAGTG            |
| 9                 | F         | AGTCTATGACATGAACACTGG            |
|                   | R         | AAATGGCTGATTGAGTGG              |
| 10                | F         | GGTAGCAGAACCACAGCC              |
|                   | R         | TGTTCTGAGACGGC                   |
| 11                | F         | GAACAAAGATTCGACTAACC            |
|                   | R         | GAAACTCCATCTCTTTGC              |
| 12                | F         | ATCCATGGCAGATGCC                |
|                   | R         | TTCTTGTTGAGGCG                   |
| 13                | F         | CCGAGAATGACTCTTTACTGCG          |
|                   | R         | GCATCCACATTTAAGGCC            |
| 14                | F         | TTGGAGATTTGTGATGCC            |
|                   | R         | GACGGGATGTCAGTTCCC          |
| 15                | F         | GAAGATGCCCGGTATTGG            |
|                   | R         | TGTCATTCTGATCCTCAG          |
| 16                | F         | TTCTGGAACCTGACATCG            |
|                   | R         | GGTTCTAGCCAGTGATGCG          |
| 17                | F         | CTGGTAAGGCGTGGCAAACC         |
|                   | R         | TCCAGCACAATAGCG                  |
| 18                | F         | GCTAACCTGACGTCAAGC          |
|                   | R         | ATCCAGGCCATACCTGCG                  |
|   | F      | R        |
|---|--------|----------|
| 19| ACGACCATTCTGGATAACC | CCTTCTTGTCACCTGTC |
| 20| TGTTAGACTTCAGACCCCTCG | GGCGGCACAAATTGAC |
| 21| GCAGTGCGAGCATATCG | GCCGTGTAAGTTGGAGTC |
| 22| ACCACAGATACCCTATGTC | CCAAGCTGTTGAAAGCG |
| 23| AGGAATGGGATTCCAGCC | TGACAATCACCCTTTCAG |
| 24| CTCCCTGAAATTCAATGG | AACAAAAATCCGATTC |
| 25| CCATCAAGGACTGCTACC | AACAAAAATCCGATTC |

645

646
Table 2. Summary of SNPs and amino acid changes between five samples of WT VEEV TC-83 and reference sequence (GenBank Accession L01443.1). All SNPs appearing over 1% in at least one sample are shown. Numbers under sample columns indicate the percentage of SNPs present in that sample compared to the reference sequence. A dash indicates the SNP did was not observed above 1% in that sample.

| Type   | Nucleotide Change | Amino Acid Change | Gene | Sample 1 | Sample 2 | Sample 3 | Sample 4 | Sample 5 |
|--------|-------------------|-------------------|------|----------|----------|----------|----------|----------|
| SNP    | C1151T            | N369N             | nsP1 | 7.26     | 5.11     | 5.14     | 5.92     | 6.34     |
| Insertion | -2253A        | N/A               | nsP2 | 1.86     | 3.83     | 2.42     | -        | -        |
| Insertion | -2501T        | N/A               | nsP2 | 3.17     | 3.12     | 3.44     | -        | -        |
| SNP    | C2627A            | D326E             | nsP2 | -        | 1.51     | 1.08     | -        | -        |
| Insertion | -2628A        | N/A               | nsP2 | 4.61     | 6.36     | 5.49     | 5.01     | 2.78     |
| SNP    | T2873A            | H408Q             | nsP2 | -        | 1.04     | -        | -        | -        |
| SNP    | A5151C            | I374L             | nsP3 | -        | 1.4      | 1.58     | -        | -        |
| SNP    | A5573G            | S514S             | nsP3 | -        | 1.05     | -        | -        | -        |
| SNP    | T7208C            | P502P             | nsP4 | 99.86    | 99.74    | 99.95    | 99.94    | 99.88    |
| SNP    | G7787A            | G76R              | C    | 1.36     | -        | -        | -        | -        |
| Insertion | -9964T        | N/A               | 6K   | -        | 2.98     | 3.24     | -        | -        |
| SNP    | C9987T            | A52V              | 6K   | -        | 1.79     | 1.7      | -        | -        |
| SNP    | T10759C           | F253F             | E1   | 1.82     | -        | -        | -        | -        |
| Insertion | -10768T        | N/A               | E1   | -        | -        | -        | 1.52     | -        |
| SNP    | G11149T           | P383P             | E1   | 1.57     | 1.05     | -        | -        | -        |
| SNP    | C11386T           | noncoding         | N/A  | 99.75    | 100      | 100      | 100      | 100      |
### Table 3. Summary of SNPs and amino acid changes found at increasing concentrations of ML336 in Vero 76.

| Nucleotide Change | Amino Acid Change | Gene | Replicate | 50 nM | 100 nM | 200 nM | 400 nM | 800 nM | 1600 nM | 3200 nM |
|-------------------|------------------|------|-----------|-------|--------|--------|--------|--------|---------|---------|
| C692T             | R220C            | nsP1 | R4        | -     | -      | 5.65   | 12.95  | 35.18  | 50.61   | 33.17   |
| C920T             | I292I            | nsP1 | R3        | -     | 9.59   | 3.59   | -      | -      | -       | -       |
| G1938C            | E97Q             | nsP2 | R1        | 12.42 | -      | 16.55  | 6.72   | -      | 20.34   | -       |
| C920T             | I292I            | nsP1 | R3        | 2.25  | 4.42   | 3.08   | 8.01   | 15.57  | 20.6    | -       |
| A2002T            | E118V            | nsP2 | R1        | -     | 39.24  | 2.06   | -      | 1.22   | 1.63    | 2.16    |
| T2453C            | I268I            | nsP2 | R3        | -     | 48.76  | 84.54  | >99.99 | >99.99 | >99.99  | >99.99  |
| T4007C            | G786G            | nsP2 | R1        | -     | 32.99  | 41.52  | 40.43  | 39.84  | 31.60   | -       |
| G5414A            | A616A            | nsP3 | R1        | 14.24 | 32.72  | 42.12  | 42.28  | 43.81  | 38.16   | -       |
| A59562T           | Y87F             | nsP4 | R2        | -     | 74.60  | 88.35  | 84.82  | 82.66  | 66.62   | -       |
| C6330A            | Q210R            | nsP4 | R1        | 14.9  | 32.93  | 42.26  | 45.95  | 48.88  | 51.23   | -       |
| C63310A           | Q10R             | nsP4 | R2        | -     | 73.84  | 88.01  | 87.14  | 88.04  | 84.43   | -       |
| C63310A           | Q210R            | nsP4 | R3        | 1.67  | 53.61  | 84.16  | 95.15  | 93.62  | 95.72   | 95.59   |
| A63310A           | Q210R            | nsP4 | R2        | -     | 78.22  | 93.61  | 94.89  | 96.37  | 95.06   | -       |
| A63310A           | Q210R            | nsP4 | R4        | 14.9  | 56.25  | 70.89  | 79.65  | 85.50  | 89.94   | -       |
| A59562T           | Y87F             | nsP4 | R1        | 14.9  | 32.93  | 42.26  | 45.95  | 48.88  | 51.23   | -       |
| A59562T           | Y87F             | nsP4 | R2        | -     | 73.84  | 88.01  | 87.14  | 88.04  | 84.43   | -       |
| C6330A            | Q210R            | nsP4 | R3        | 1.67  | 53.61  | 84.16  | 95.15  | 93.62  | 95.72   | 95.59   |
| A63310A           | Q210R            | nsP4 | R4        | 14.9  | 56.25  | 70.89  | 79.65  | 85.50  | 89.94   | -       |
| A63310A           | Q210R            | nsP4 | R1        | 2.26  | 21.48  | 14.46  | 9.73   | 5.14   | -       | -       |
| G6617A            | Q10R             | nsP4 | R2        | -     | 74.32  | 90.42  | 91.54  | 92.68  | 92.59   | -       |
| C6942T            | H414Y            | nsP4 | R1        | -     | 11.4   | -      | -      | -      | -       | -       |
| C7367T            | R558R            | nsP4 | R1        | 1.03  | 10.00  | 2.15   | -      | -      | -       | -       |
| A10285T           | S275S            | E1   | R3        | 30.90 | -      | -      | -      | -      | -       | -       |
| A10897P           | S275P            | E1   | R1        | -     | 34.99  | 42.79  | 46.83  | 48.27  | 45.84   | -       |
| A10930T           | S310S            | E1   | R1        | -     | 21.08  | 25.95  | 25.00  | 25.91  | 24.81   | -       |
Table 4. Summary of the SNPs and amino acid changes for VEEV TC-83/3200 passaged in the absence of ML336. P1, P2, etc. represent each successive passage.

| Replicate | Nucleotide Change | Amino Acid Change | Gene | 3200 nM (Original)* | P1 | P2 | P3 | P4 | P5 | P6 | P7 |
|-----------|-------------------|-------------------|------|---------------------|----|----|----|----|----|----|----|
| R1        | A2002T            | E118V             | nsP2 | 2.16                | -  | -  | -  | 2.69 | 3.21 | 1.83 |
|           | T4007C            | G786G             | nsP2 | 31.60               | 52.29 | 50.26 | 51.48 | 42.64 | 43.57 | 41.04 | 46.78 |
|           | G5414A            | A461A             | nsP3 | 38.16               | 53.1  | 53.7  | 52.11 | 47.9  | 51.01 | 50.37 |
|           | A5962T            | Y87F              | nsP4 | 51.23               | 52.8  | 51.19 | 51.04 | 54.33 | 51.9  | 49.53 | 50.85 |
|           | A6331G            | Q210R             | nsP4 | 89.94               | 93.13 | 93.3  | 93.24 | 93.93 | 93.53 | 92.69 |
|           | A6332T            | Q210H             | nsP4 | 5.14                | 5.62  | 5.25  | 5.23  | 4.57  | 5.35  | 6.07  |
|           | C10849T           | P283P             | E1   | 45.84               | 56.7  | 58.35 | 58.8  | 54.84 | 55.24 | 54.76 |
| R2        | A1938G            | E97Q              | nsP2 | 20.6                | -     | -     | -     | -     | -     | -     | -     |
|           | G5414A            | A461A             | nsP3 | 66.62               | 91.92 | 92.47 | 92.13 | 88.45 | 91.48 |
|           | A5962T            | Y87F              | nsP4 | 84.43               | 92.56 | 92.59 | 92.76 | 91.96 |
|           | A6331G            | Q210R             | nsP4 | 95.06               | 98.85 | 99.1  | 99.07 |
|           | G6617A            | R305R             | nsP4 | 92.59               | 92.71 | 91.46 | 91.55 |
| R3        | T2453C            | E289I             | nsP2 | -                   | 96.81 | 97.14 | 97.22 | 90.92 | 92.32 | 90.92 | 97.84 |
|           | C6330A            | Q210K             | nsP4 | 95.59               | 97.8  | 97.13 | 98.25 | 98.45 | 98.12 | 98.02 | 98.16 |
| R4        | C692T             | R220C             | nsP1 | 33.17               | 73.31 | 75.47 | 83.65 | 56.93 | 69.25 | 54.86 | 84.95 |
|           | A6331G            | Q210R             | nsP4 | 85.12               | 99.25 | 99.30 | 99.26 | 99.99 | 99.13 | 99.99 | 99.37 |

*Values under the 3200 nM column are the same as the 3200 nM column in Table 2.

Blanks indicate depth of coverage was too low to analyze at that nucleotide position.
Table 5. Summary of SNPs and amino acid changes found at increasing concentrations of ML336 in SVGA.

| Nucleotide Change | Amino Acid Change | Gene | Replicate | 50 nM | 100 nM | 200 nM | 400 nM | 800 nM | 1600 nM | 3200 nM |
|-------------------|-------------------|------|-----------|-------|--------|--------|--------|--------|---------|---------|
| C803T             | D253D             | nsP1 | R2        | -     | 8.16   | 17.91  | 9.82   | 2.33   | -       | -       |
| A1939C            | E97A              | nsP2 | R4        | -     | 6.02   | 14.06  | 13.86  | 14.62  | 18.18   |         |
| G1995A            | D116N             | nsP2 | R2        | -     | 10.34  | 20.31  | 12.81  | 3.28   | -       | -       |
| A2002T            | E118V             | nsP2 | R1        | -     | 29.64  | 5.62   | -      | -      | -       | -       |
|                  |                   |      | R2        | -     | 14.83  | 2.34   | -      | -      | -       | -       |
|                  |                   |      | R3        | -     | 15.53  | 2.46   | -      | -      | -       | -       |
| C3579T            | P644S             | nsP2 | P1        | -     | 3.19   | -      | 41.57  | 51.17  | 55.36   | 45.54   |
| G5414A            | A461A             | nsP3 | R1        | -     | 1.56   | 4.02   | 7.48   | 6.6    | 10.36   | 11.32   |
|                  |                   |      | R2        | -     | 4.9    | 12.04  | 16.63  | 14.59  | 22.94   | 33.26   |
|                  |                   |      | R3        | -     | 4.09   | 7.17   | 7.91   | 4.82   | 7.53    | 12.01   |
|                  |                   |      | R4        | -     | 11.74  | 23.06  | 22.09  | 21.6   | 35.88   |         |
| A5962T            | Y87F              | nsP4 | R1        | -     | 1.27   | 3.95   | 7.28   | 8.94   | 7.55    | 9.99    |
| A6331G            | Q210R             | nsP4 | R2        | -     | 4.15   | 13.55  | 14.82  | 17.75  | 25.65   | 34.43   |
|                  |                   |      | R3        | -     | 3.21   | 8.42   | 7.52   | 9.32   | 9.72    | 13.65   |
|                  |                   |      | R4        | -     | 3.19   | 11.29  | 23.38  | 23.81  | 25.35   | 34.12   |
| A6332T            | Q210H             | nsP4 | R1        | -     | 1.19   | 4.84   | 7.15   | 6.45   | 8.01    | 10.61   |
|                  |                   |      | R2        | -     | -      | 12.28  | 16.56  | -      | 19.12   | 36.27   |
|                  |                   |      | R3        | -     | 2.44   | 8.17   | 8.11   | 6.99   | 9.34    | 13.56   |
|                  |                   |      | R4        | -     | 11.51  | 22.38  | 21.26  | 24.85  | 30.37   |         |
|                  |                   |      | R2        | -     | 40.32  | 58.91  | -      | 77.3   | 61.54   |         |
|      | A6332C | Q210H  | nsP4 | R3    | 22.55 | 75.97 | 86.54 | 91.33 | 89.24 | 84.69 |
|------|--------|--------|------|-------|-------|-------|-------|-------|-------|-------|
| R4   |        |        |      | -     | 19.6  | 66.07 | 71.83 | 71.46 | 66.67 |
| A6341T | E213D  | nsP4  | R1   | -     | 4.38  | 29.28 | 45.75 | 59.85 | 55.26 | 51.95 |
|      |        |        | R1   | -     | 10.52 | -     | 15.88 | 5.34  | -     | -     |
|      |        |        | R2   | -     | -     | 15.08 | 9.31  | -     | -     | -     |
| G6617A | R305R  | nsP4  | R1   | -     | -     | -     | 4.95  | 7.69  | 6.87  | 12.16 |
|      |        |        | R2   | -     | 3.03  | 11.55 | 16.77 | 15.51 | 21.85 | 32.26 |
|      |        |        | R3   | -     | 3.27  | 7.79  | 8.04  | 5.82  | 9.31  | 12.64 |
|      |        |        | R4   | -     | 5.24  | 9.63  | 9.49  | 11.18 | 13.26 |
| C6976T | A425V  | nsP4  | R1   | -     | 19.45 | 9.03  | -     | -     | -     | -     |
|      |        |        | R4   | 1.81  | 17.93 | 2.47  | -     | -     | -     | -     |
| G8570A | E3K    | E2    | R1   | -     | -     | -     | -     | -     | -     | -     |
|      |        |        |       | -     | -     | -     | -     | -     | -     | -     |
| C8795T | P87S   | E2    | VC2  | -     | -     | -     | 4.63  | 33.49 | 56.07 | 67.62 |
|      |        |        | VC3  | -     | -     | -     | -     | -     | 10.09 | 26.4  |
| A9107C | S182R  | E2    | VC1  | -     | -     | -     | -     | -     | -     | 39.52 |
| A9210G | Q216R  | E2    | R1   | -     | -     | -     | -     | -     | 5.31  | 11.83 |
| C10321T | Y107Y  | E1    | VC1  | -     | -     | -     | -     | -     | 26.96 | 45.45 |
Table 6. Summary of point mutations and amino acid changes found in TC-83 extracted from C3H/HeN mouse brains.

| Nucleotide Change | Amino Acid Change | Gene | Treatment | Sample | Day Euthanized | SNP Percentage |
|------------------|------------------|------|-----------|--------|----------------|----------------|
| T1657C           | V3A              | nsP2 | PBS       | B1     | 7              | 13.68          |
| G3033A           | E462K            | nsP2 | PBS       | C4     | 7              | 11.68          |
| C3070T           | A474V            | nsP2 | PBS       | D3     | 8              | 84.68          |
| C3458T           | N603N            | nsP2 | PBS       | C1     | 8              | 17.81          |
| G3831A           | A728T            | nsP2 | PBS       | D2     | 7              | 65.92          |
| C4024T           | A792V            | nsP2 | PBS       | D1     | 8              | 23.38          |
| A4894G           | Q288R            | nsP3 | PBS       | B2     | 7              | 52.4           |
| C5606G           | S525R            | nsP3 | PBS       | D1     | 8              | 13.13          |
| G7282A           | R527K            | nsP4 | PBS       | C2     | 7              | 13.14          |
| G8042-           | N/A              | C    | PBS       | C4     | 7              | 12.52          |
| A8108-           | N/A              | C    | PBS       | D1     | 8              | 15.42          |
| C9481T           | Y306Y            | E2   | PBS       | C1     | 8              | 16.78          |
| C9850T           | S6S              | 6K   | ML336     | C4     | 14             | 84.78          |
| A9862G           | L10L             | 6K   | ML336     | C2     | 7              | 10.74          |
| C10861T          | F287F            | E1   | PBS       | A2     | 4              | 81.27          |
|                  |                  |      | PBS       | D3     | 8              | 9.52           |
